Cleanaway To Power Sustainability Commitment with AMCS
29.5.2024 12:09:00 EEST | Business Wire | Press release
AMCS, a global leader of sustainability software for foundational industries, is pleased to announce that Cleanaway has chosen AMCS for its enterprise fulfillment and transportation solution. This strategic partnership will help propel Cleanaway's multi-phased 'CustomerConnect' project forward, leveraging data and AI to power more efficient operations and enhance the customer experience.
Cleanaway is Australia’s leading waste management and resource recovery provider. Commanding over 300 sites across the nation, all waste streams, and generating over AUD $3.5 billion in annual revenue, Cleanaway has chosen AMCS to modernize its fulfillment operations and enable the company to further advance its purpose of making a sustainable future possible together. The solution will serve as Cleanaway’s central fulfillment hub, encompassing their commercial fleet of trucks and replacing a complex array of 15 separate legacy systems previously utilized by Cleanaway.
"We were seeking a robust, scalable solution that aligned with our requirements and AMCS stood out," said Matt French, Program Director, Cleanaway. "The AMCS Platform and supporting products will provide a future-proof solution that will evolve with our expanding requirements, enhancing the customer experience and employee satisfaction, while helping drive operational efficiencies across all of our business units.”
Cleanaway’s fulfillment hub will be comprised of the following suite of products from AMCS Group: AMCS Platform, Smart Dispatch, Route Planner, Fleet Planner, Guided Navigation, Site Safety Module, and Fleet Maintenance. The unified, modern solution will be enriched with multiple supporting APIs, offering an intuitive user experience, real-time data with superior visualization capabilities and intelligence, as well as enterprise-grade scalability.
"We’re delighted to support Cleanaway with a modern, cloud-based fulfillment platform,” said Jimmy Martin, co-founder and CEO, AMCS Group. “Cleanaway mirrors our commitment to a more sustainable future and I’m impressed with Cleanaway’s vision and the highly capable employees and resources they have dedicated to this project. Together, with our global domain expertise in the waste and recycling industry, we’ll ensure that our purpose-built solution will support Cleanaway's digital transformation and help meet their ambitious business and sustainability goals."
The partnership endeavors to deliver substantial benefits for Cleanaway, including an improved customer experience, enhanced employee satisfaction through efficient information sharing and reporting, opportunities for revenue growth, and improved operational and resource efficiencies.
About Cleanaway
Cleanaway Waste Management Ltd is Australia’s leading waste management and resource recovery company, with a national network of unique collection, processing, treatment, and landfill assets. Cleanaway operates from more than 300 locations and employs more than 7,700 people.
Our philosophy is that all waste is a resource and we aim to incorporate recovery, recycling, and reuse throughout our operations and those of our customers. Our mission is to make a sustainable future possible together. Learn more at www.cleanaway.com.au
About AMCS
At AMCS we are focused on Performance Sustainability – enabling resource-intensive industries to boost sustainability and profitability. Built on decades of experience, our purpose-built software solutions are designed by people who understand your business, providing practical solutions for the resources, waste, recycling, transportation, manufacturing, and utilities industries.
Headquartered in Ireland, and with offices in Europe, the USA, and Australia, AMCS is a global market leader with over 1,300 mission-driven team members. The combined expertise of our team allows AMCS to deliver innovative solutions and extensive insight, helping customers to drive growth and achieve lasting success. As a trusted global partner, we work with 5000+ customers in more than 80 countries delivering digital solutions that create meaningful and measurable impact by increasing customer satisfaction, enhancing sustainability, and boosting margins.
At AMCS, we're ready to innovate with you - deploying our experts, processes, and technology to drive your business forward and prepare you for success in a more sustainable, net zero carbon future. Learn more at www.amcsgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529784008/en/
Contact information
Media
Dwayne Weppler
AMCS Group
dwayne.weppler@amcsgroup.com
1-226 581 5166
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 15:00:00 EEST | Press release
Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and training workloads, all deployed in data centers throughout the Kingdom. “The future of artificial intelligence depends on the ability to combine world-class inf
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions, expands our addressable market — more than doubling our revenue opportunity per gigawatt of delivered capacity — and allows us to scale both our offerings and the globa
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom